Drugs / CPD-1061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02134340 | Jun 2014 → Jun 2016 | cancer | Centre for Probe Development and Commercialization | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPD-1061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02134340 ↗ |
| Route | Intravenous | “An intravenous dose of 0.4, 1.4 or 6 mg/kg” NCT02134340 ↗ |